読み込み中
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
前日終値
$0.7212
+$0.0208 · +2.97%
市場前
$0.7228
+$0.0016 · +0.22%
10月12日 7:38 ET
日中の時刻はETです。市場データは遅延する場合があります。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
日中レンジ
現在 $0.7212
52週レンジ
現在 $0.7212
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
97
大幅な割安
センチメント
46
まちまち
リスク
66
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
日中レンジ
現在 $0.7212
52週レンジ
現在 $0.7212
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI743.44万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM407.3万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF245.67万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO115.61万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC48.08万0.04%13.17億 USD0.60%$183+0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT41.41万0.00%980.88億 USD0.03%$169.66+0.64%
Virtus Biotech Clinical Trials ETFBBC28.87万0.70%4099.65万 USD0.65%$44.1456+2.08%
Vanguard Russell 2000 Value ETFVTWV18.61万0.01%14億 USD0.06%$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVirtus Biotech Clinical Trials ETFBBCVanguard Russell 2000 Value ETFVTWVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
